| VIDAC PHARMA HLDG PLC LS1 |
| Großbritannien |
| Gesundheit |
| GB00BM9XQ619 / A3DTUQ |
| T9G (Frankfurt) |
| FRA:T9G, ETR:T9G, T9G:GR |
| - |
| https://vidacpharma.com/ |
|
Vidac Pharma Holding Plc, an investment holding company, engages in the discovery and development of anticancer medicines. The company is developing VDA-1102 CTCL which is in phase 2 clinical trials for the treatment of cutaneous T cell lymphoma (CTC..
>Volltext.. |
| 27.25 Mio. EUR |
| 27.44 Mio. EUR |
| - |
| -2.15 Mio. EUR |
| -2.78 Mio. EUR |
| -0.05 EUR |
| 0.41 Mio. EUR |
| 0.22 Mio. EUR |
| -2.07 Mio. EUR |
| 0.13 |
| - |
| -92.82% |
| - |
| - |
| - |
| VIDAC PHARMA |
| 10.11.26 |
|
||||
|